By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin Therapeutics Receives U.S. Patent Notice Of Allowance For Use Of Pectin Compounds To Reduce Fibrosis In Multiple Diseases 8/13/2015 7:45:31 AM
Galectin Therapeutics Provides Phase II NASH Program Update and Reports Second Quarter 2015 Financial Results 8/10/2015 7:40:34 AM
Exalenz Bioscience Announces Collaboration With Galectin Therapeutics To Use BreathID To Monitor Patients With Cirrhosis Associated With NASH 8/3/2015 6:24:23 AM
Galectin Therapeutics Appoints Adam E. Allgood, Pharm.D., R.Ph., As Executive Director Of Clinical Development 7/16/2015 7:39:04 AM
Galectin Therapeutics Initiates Enrollment For GR-MD-02 Phase II Clinical Trial In NASH With Cirrhosis 6/29/2015 7:27:47 AM
Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director 6/3/2015 7:35:37 AM
Galectin Therapeutics To Present At LD Micro Invitational Conference 5/28/2015 7:51:24 AM
Galectin Therapeutics To Webcast Corporate Update Following Annual Meeting Of Stockholders 5/15/2015 10:16:56 AM
Galectin Therapeutics Reports No Drug-Drug Interaction Between GR-MD-02 And Midazolam 5/14/2015 1:30:17 PM
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase II Nash Program 5/11/2015 7:46:01 AM